{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:40:02Z","timestamp":1759153202232,"version":"3.44.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,29]]},"DOI":"10.7759\/cureus.93484","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:09:58Z","timestamp":1759151398000},"source":"Crossref","is-referenced-by-count":0,"title":["Management of Diabetic Kidney Disease With Persistent Hypotension: A Case of Lifestyle-Driven Renal Recovery"],"prefix":"10.7759","author":[{"given":"Sungmin","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okoro","family":"Obioha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoobin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"KDIGO Diabetes Work Group","year":"2022","unstructured":"KDIGO Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022, 102:S1-S127. 10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-SINT","article-title":"Introduction and methodology: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. Introduction and methodology: standards of care in diabetes-2024. Diabetes Care. 2024, 47:S1-4. 10.2337\/dc24-SINT","journal-title":"Diabetes Care"},{"key":"ref3","article-title":"Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view","volume":"10(6)","author":"Gansevoort TR","year":"2015","unstructured":"Gansevoort TR, Heerspink LJH. Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view. Clin J Am Soc Nephrol. 2015, 10(6):1079-1088.","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2022.18.2.102","article-title":"Non-albuminuric diabetic kidney disease phenotype: beyond albuminuria","volume":"18","author":"D'Marco L","year":"2022","unstructured":"D'Marco L, Guerra-Torres X, Viejo I, et al.. Non-albuminuric diabetic kidney disease phenotype: beyond albuminuria. touchREV Endocrinol. 2022, 18:102-5. 10.17925\/EE.2022.18.2.102","journal-title":"touchREV Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian M","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B, et al.. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013, 24:302-8. 10.1681\/ASN.2012070718","journal-title":"J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.12.025","article-title":"Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Cheung AK","year":"2019","unstructured":"Cheung AK, Chang TI, Cushman WC, et al.. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019, 95:1027-36. 10.1016\/j.kint.2018.12.025","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton PK","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al.. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018, 71:e13-e115. 10.1161\/HYP.0000000000000065","journal-title":"Hypertension"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-14-4-251","article-title":"Cardiac autonomic neuropathy in diabetes mellitus","volume":"14","author":"Agashe S","year":"2018","unstructured":"Agashe S, Petak S. Cardiac autonomic neuropathy in diabetes mellitus. Methodist Debakey Cardiovasc J. 2018, 14:251-6. 10.14797\/mdcj-14-4-251","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030671","article-title":"Cardiac autonomic neuropathy in diabetes mellitus: pathogenesis, epidemiology, diagnosis and clinical implications: a narrative review","volume":"14","author":"Gogan A","year":"2025","unstructured":"Gogan A, Potre O, Avram VF, et al.. Cardiac autonomic neuropathy in diabetes mellitus: pathogenesis, epidemiology, diagnosis and clinical implications: a narrative review. J Clin Med. 2025, 14:10.3390\/jcm14030671","journal-title":"J Clin Med"},{"key":"ref10","article-title":"Nonalbuminuric diabetic kidney disease and risk of all-cause mortality and cardiovascular and kidney outcomes","volume":"45","author":"Kristensen SL","year":"2022","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al.. Nonalbuminuric diabetic kidney disease and risk of all-cause mortality and cardiovascular and kidney outcomes. Diabetes Care. 2022, 45:1429-1437.","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393(10166)","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019, 393(10166):31-39. 10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial","volume":"143","author":"Ye N","year":"2021","unstructured":"Ye N, Jardine MJ, Oshima M, et al.. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation. 2021, 143:1735-49. 10.1161\/CIRCULATIONAHA.120.048740","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7(10)","author":"Kristensen SL","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019, 7(10):776-785. 10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13598","article-title":"Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study","volume":"12","author":"Kuwata H","year":"2021","unstructured":"Kuwata H, Yabe D, Murotani K, et al.. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. J Diabetes Investig. 2021, 12:2162-71. 10.1111\/jdi.13598","journal-title":"J Diabetes Investig"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.08.024","article-title":"Gaps in hypertension guidelines for patients with chronic kidney disease","volume":"73(2)","author":"Ku E","year":"2019","unstructured":"Ku E, Grams ME, Rebholz CM, et al.. Gaps in hypertension guidelines for patients with chronic kidney disease. Amr Jr Kid Dis. 2019, 73(2):235-243. 10.1053\/j.ajkd.2018.08.024","journal-title":"Amr Jr Kid Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/299093-management-of-diabetic-kidney-disease-with-persistent-hypotension-a-case-of-lifestyle-driven-renal-recovery","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:09:59Z","timestamp":1759151399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/299093-management-of-diabetic-kidney-disease-with-persistent-hypotension-a-case-of-lifestyle-driven-renal-recovery"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.93484","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}